These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23104163)

  • 1. A case of hepatopulmonary syndrome solved by mycophenolate mofetil (an inhibitor of angiogenesis and nitric oxide production).
    Moreira Silva H; Reis G; Guedes M; Cleto E; Vizcaíno JR; Kelly D; Gennery AR; Santos Silva E
    J Hepatol; 2013 Mar; 58(3):630-3. PubMed ID: 23104163
    [No Abstract]   [Full Text] [Related]  

  • 2. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome.
    Almeida JA; Riordan SM; Liu J; Galhenage S; Kim R; Bihari D; Wegner EA; Cranney GB; Thomas PS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):341-6. PubMed ID: 17353701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducible nitric oxide synthase inhibition by mycophenolic acid.
    Miljkovic Dj; Markovic M; Trajkovic V
    Mini Rev Med Chem; 2004 Sep; 4(7):741-6. PubMed ID: 15379641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatopulmonary syndrome: role of nitric oxide and clinical aspects.
    Rolla G
    Dig Liver Dis; 2004 May; 36(5):303-8. PubMed ID: 15191196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
    Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L
    J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mycophenolate mofetil, a possible new immunosuppresant].
    Weberová J; Voboril R; Semecký V
    Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine for hepatopulmonary syndrome?
    Altschuler EL; Kast RE
    Med Hypotheses; 2004; 62(3):446-7. PubMed ID: 14975520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents.
    Añel RM; Sheagren JN
    Clin Infect Dis; 2001 May; 32(10):E131-6. PubMed ID: 11317264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome.
    Jounieaux V; Leleu O; Mayeux I
    Intensive Care Med; 2001 Jun; 27(6):1103-4. PubMed ID: 11497151
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycophenolate mofetil: new applications for this immunosuppressant.
    Moder KG
    Ann Allergy Asthma Immunol; 2003 Jan; 90(1):15-19; quiz 20, 78. PubMed ID: 12546332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil in primary glomerulopathies.
    Sepe V; Libetta C; Giuliano MG; Adamo G; Dal Canton A
    Kidney Int; 2008 Jan; 73(2):154-62. PubMed ID: 17989649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European experience with mycophenolate mofetil. European Mycophenolate Mofetil Cooperative Study Group.
    Groth CG
    Transplant Proc; 1996 Dec; 28(6 Suppl 1):30-3. PubMed ID: 8962411
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mycophenolate mofetil in lupus nephritis treatment].
    Savio V; Alba P; Babini AM
    Rev Fac Cien Med Univ Nac Cordoba; 2012; 69(4):219-23. PubMed ID: 23751789
    [No Abstract]   [Full Text] [Related]  

  • 14. [New trends in chemotherapy of systemic lupus erythematosus: treatment with mycophenolate mofetil].
    Shekshina SV; Kliukvina NG; Nasonov EL; Nasonova VA
    Klin Med (Mosk); 2002; 80(4):26-30. PubMed ID: 12043258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil.
    Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
    Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
    Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
    Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
    Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
    Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome.
    Brussino L; Bucca C; Morello M; Scappaticci E; Mauro M; Rolla G
    Lancet; 2003 Jul; 362(9377):43-4. PubMed ID: 12853200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-α neutralization improves experimental hepatopulmonary syndrome in rats.
    Liu L; Liu N; Zhao Z; Liu J; Feng Y; Jiang H; Han D
    Liver Int; 2012 Jul; 32(6):1018-26. PubMed ID: 22672643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil.
    Goyal S; Nousari HC
    J Am Acad Dermatol; 2001 Jul; 45(1):142-4. PubMed ID: 11423853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.